Literature DB >> 21455625

Clinicopathological features of triple-negative breast cancer in Taiwanese women.

Kuo Yao-Lung1, Chen Dar-Ren, Chang Tsai-Wang.   

Abstract

BACKGROUND: The goal of this study was to identify prognostic factors that influence the survival outcome of Taiwanese women with triple-negative breast cancer (TNBC).
METHODS: Of 709 patients with breast cancer diagnosed between January 2002 and December 2005, 152 patients (21.4 %) were diagnosed with TNBC. The overall survival and disease-free survival were estimated using the Kaplan-Meier method and compared between groups using the log-rank test. Univariate and multivariate analyses were used to identify the prognostic factors, and the prognostic significance of these factors in TNBC patients was reviewed.
RESULTS: The median follow-up time was 70.5 months. Kaplan-Meier analysis showed significant difference between the tumor subgroups (TNBC vs. non-TNBC) in 5-year overall survival (p = 0.01) and 5-year disease-free survival (p < 0.0001). Univariate analysis showed that tumor subgroup (TNBC vs. non-TNBC) was a significant predictor of 5-year overall survival and disease-free survival. Tumor size, lymph node status, stage, grade, estrogen receptor status, progesterone receptor status, and HER2 status were also significant. In the multivariate analysis, only tumor size, lymph node status, and grade were significantly related to 5-year overall survival and disease-free survival. In TNBC patients, nodal status was significantly related to 5-year overall survival (HR = 7.47, p < 0.0001) and 5-year disease-free survival (HR = 3.913, p = 0.001).
CONCLUSION: In TNBC, nodal status is a prognostic indicator of survival. The TNBC subgroup had a worse pattern of relapse compared to the non-TNBC, irrespective of nodal negative or nodal positive breast cancer patients. We suggest that this subgroup should receive aggressive treatment to prevent early recurrence or death. Further prospective clinical trials are warranted to identify a more efficient treatment regimen to improve the prognosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21455625     DOI: 10.1007/s10147-011-0211-9

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  24 in total

Review 1.  Revision of breast cancer staging: the 6th edition of the TNM Classification.

Authors:  S Eva Singletary; Frederick L Greene
Journal:  Semin Surg Oncol       Date:  2003

Review 2.  Inhibitors of growth factor signalling.

Authors:  A E Wakeling
Journal:  Endocr Relat Cancer       Date:  2005-07       Impact factor: 5.678

3.  Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.

Authors:  Richard S Finn; Judy Dering; Charles Ginther; Cindy A Wilson; Padraic Glaspy; Nishan Tchekmedyian; Dennis J Slamon
Journal:  Breast Cancer Res Treat       Date:  2007-02-01       Impact factor: 4.872

Review 4.  Triple-negative breast cancer: therapeutic options.

Authors:  Susan Cleator; Wolfgang Heller; R Charles Coombes
Journal:  Lancet Oncol       Date:  2007-03       Impact factor: 41.316

5.  The epidemiology of triple-negative breast cancer, including race.

Authors:  Katrina F Trivers; Mary Jo Lund; Peggy L Porter; Jonathan M Liff; Elaine W Flagg; Ralph J Coates; J William Eley
Journal:  Cancer Causes Control       Date:  2009-04-03       Impact factor: 2.506

Review 6.  Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.

Authors:  Ana Bosch; Pilar Eroles; Rosa Zaragoza; Juan R Viña; Ana Lluch
Journal:  Cancer Treat Rev       Date:  2010-01-08       Impact factor: 12.111

7.  Triple negative breast cancer: clinicopathological characteristics and treatment strategies.

Authors:  Futoshi Akiyama; Hirotaka Iwase
Journal:  Breast Cancer       Date:  2009       Impact factor: 4.239

8.  Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.

Authors:  Hirotaka Iwase; Junichi Kurebayashi; Hitoshi Tsuda; Tomohiko Ohta; Masafumi Kurosumi; Kazuaki Miyamoto; Yutaka Yamamoto; Takuji Iwase
Journal:  Breast Cancer       Date:  2009-05-23       Impact factor: 4.239

9.  The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.

Authors:  Jiyoung Rhee; Sae-Won Han; Do-Youn Oh; Jee Hyun Kim; Seock-Ah Im; Wonshik Han; In Ae Park; Dong-Young Noh; Yung-Jue Bang; Tae-You Kim
Journal:  BMC Cancer       Date:  2008-10-23       Impact factor: 4.430

10.  EGFR associated expression profiles vary with breast tumor subtype.

Authors:  Katherine A Hoadley; Victor J Weigman; Cheng Fan; Lynda R Sawyer; Xiaping He; Melissa A Troester; Carolyn I Sartor; Thais Rieger-House; Philip S Bernard; Lisa A Carey; Charles M Perou
Journal:  BMC Genomics       Date:  2007-07-31       Impact factor: 3.969

View more
  7 in total

1.  Mammographic and clinicopathological features of triple-negative breast cancer.

Authors:  B Gao; H Zhang; S-D Zhang; X-Y Cheng; S-M Zheng; Y-H Sun; D-W Zhang; Y Jiang; J-W Tian
Journal:  Br J Radiol       Date:  2014-04-15       Impact factor: 3.039

2.  Pattern of distant recurrence according to the molecular subtypes in Korean women with breast cancer.

Authors:  Hyung Seok Park; Shinhyuk Kim; Kiho Kim; Ho Yoo; Byung Joo Chae; Ja Seong Bae; Byung Joo Song; Sang Seol Jung
Journal:  World J Surg Oncol       Date:  2012-01-08       Impact factor: 2.754

3.  5-FU and ixabepilone modify the microRNA expression profiles in MDA-MB-453 triple-negative breast cancer cells.

Authors:  Yongshan Yao; Shenghan Chen; Xin Zhou; Li Xie; Aijun Chen
Journal:  Oncol Lett       Date:  2013-11-22       Impact factor: 2.967

4.  Computational analysis of mRNA expression profiles identifies the ITG family and PIK3R3 as crucial genes for regulating triple negative breast cancer cell migration.

Authors:  Sukhontip Klahan; Mei-Shin Wu; Edward Hsi; Chi-Cheng Huang; Ming-Feng Hou; Wei-Chiao Chang
Journal:  Biomed Res Int       Date:  2014-05-06       Impact factor: 3.411

5.  Clinical Significance of Serum IL-12 Level in Patients with Early Breast Carcinoma and Its Correlation with Other Tumor Markers.

Authors:  Samar Samir Youssef; Manal Moussa Mohammad; Lobna R Ezz-El-Arab
Journal:  Open Access Maced J Med Sci       Date:  2015-11-03

6.  Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer.

Authors:  Ju-Yi Hsu; Chee-Jen Chang; Jur-Shan Cheng
Journal:  Sci Rep       Date:  2022-01-14       Impact factor: 4.379

Review 7.  Interleukin-19 in breast cancer.

Authors:  Ying-Yin Chen; Chien-Feng Li; Ching-Hua Yeh; Ming-Shi Chang; Chung-Hsi Hsing
Journal:  Clin Dev Immunol       Date:  2013-04-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.